Novel therapies for peripheral T-cell non-Hodgkin's lymphomas

被引:20
作者
Cheson, Bruce D. [1 ]
机构
[1] Georgetown Univ Hosp, Washington, DC 20007 USA
关键词
forodesine; histone deacetylase inhibitors; monoclonal antibodies; peripheral T-cell lymphoma; pralatrexate; SUBEROYLANILIDE HYDROXAMIC ACID; PROTEASOME INHIBITOR BORTEZOMIB; LEUKEMIA GROUP-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; BENDAMUSTINE PLUS RITUXIMAB; PHASE-2 NCI MULTICENTER; MANTLE CELL; OPEN-LABEL; CLINICAL-EXPERIENCE; MONOCLONAL-ANTIBODY;
D O I
10.1097/MOH.0b013e32832ad69a
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review To review new agents under investigation for the treatment of patients with peripheral T-cell lymphoma. Recent findings New agents being evaluated in these patients include histone deacetylase inhibitors (e.g. romidepsin, vorinostat, and balinostat), purine analogs and agents that interfere with the purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and gossypol), antifols (e.g. pralatrexate), proteasome inhibitors (e.g. bortezomib), monoclonal antibodies against T-cell antigens (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox). Summary The development of rational combinations of such agents in clinical trials will be required to improve the outcome of these patients.
引用
收藏
页码:299 / 305
页数:7
相关论文
共 66 条
[1]  
[Anonymous], 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
[2]   Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor - BCX-1777 [J].
Bantia, S ;
Ananth, SL ;
Parker, CD ;
Horn, LSL ;
Upshaw, R .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (06) :879-887
[3]   A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies [J].
Bartlett, Nancy L. ;
Younes, Anas ;
Carabasi, Matthew H. ;
Forero, Andres ;
Rosenblatt, Joseph D. ;
Leonard, John P. ;
Bernstein, Steven H. ;
Bociek, R. Gregory ;
Lorenz, Jennie M. ;
Hart, Bruce W. ;
Barton, Jeremy .
BLOOD, 2008, 111 (04) :1848-1854
[4]  
Bates S, 2008, BLOOD, V112, P556
[5]   Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-Cell malignancies: A report from the children's oncology group [J].
Berg, SL ;
Blaney, SM ;
Devidas, M ;
Lampkin, TA ;
Murgo, A ;
Bernstein, M ;
Billett, A ;
Kurtzberg, J ;
Reaman, G ;
Gaynon, P ;
Whitlock, J ;
Krailo, M ;
Harris, MB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3376-3382
[6]   Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 [J].
Blum, Kristie A. ;
Johnson, Jeffrey L. ;
Niedzwiecki, Donna ;
Canellos, George P. ;
Cheson, Bruce D. ;
Bartlett, Nancy L. .
LEUKEMIA & LYMPHOMA, 2007, 48 (07) :1313-1319
[7]  
Blum KA, 2008, BLOOD, V112, P92
[8]   High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas [J].
Bremer, K .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (11) :603-609
[9]  
Chanan-Khan AA, 2005, BLOOD, V106
[10]  
Cheson BD, 2009, J CLIN ONCOL, V27